Position in LLY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$63,942,818
-$3,822,156 QoQ
Shares Held
53,311
-27.6% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
1.17%
of 13F equity value
Holder Rank
#485
of 4,605 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 34%
Shared 0%
None 66%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Voleon Capital Management LP holds $188,095,544 across 10 Drug Manufacturers - General names. LLY ranks #1 (34.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
53,311 | $63,942,818 | |
| 2 | ABBV |
AbbVie Inc.
|
172,753 | $43,471,564 | |
| 3 | MRK |
Merck & Co., Inc.
|
295,499 | $37,971,621 | |
| 4 | AZN |
Astrazeneca PLC
|
125,385 | $23,775,503 | |
| 5 | JNJ |
Johnson & Johnson
|
28,917 | $7,344,050 | |
| 6 | SNY |
Sanofi
|
89,489 | $3,817,600 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
64,106 | $3,693,787 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
23,049 | $2,912,010 |
All Filings in LLY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $63,942,818 | 53,311 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $67,764,974 | 73,676 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $43,556,784 | 40,530 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $12,181,295 | 15,965 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $14,823,542 | 19,016 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $8,055,100 | 9,753 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $5,664,936 | 7,338 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||